(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 29.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.23%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Omniab's revenue in 2025 is $26,744,000.On average, 5 Wall Street analysts forecast OABI's revenue for 2025 to be $2,885,401,235, with the lowest OABI revenue forecast at $2,740,311,526, and the highest OABI revenue forecast at $3,046,149,866. On average, 5 Wall Street analysts forecast OABI's revenue for 2026 to be $4,238,185,380, with the lowest OABI revenue forecast at $3,131,784,602, and the highest OABI revenue forecast at $5,534,450,601.
In 2027, OABI is forecast to generate $7,549,680,591 in revenue, with the lowest revenue forecast at $4,501,940,365 and the highest revenue forecast at $9,583,750,222.